Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Chieftain Capital Management in connection with the investment in Koenigsegg Automotive
Mandate

Vinge advises Chieftain Capital Management in connection with the investment in Koenigsegg Automotive

October 08, 2024

Vinge has advised Chieftain Capital Management, Inc. (”Chieftain”), a New York based family office, in its investment in the Swedish megacar manufacturer Koenigsegg Automotive AB (“Koenigsegg”).

The investment, which coincided with Koenigseggs 30th anniversary, was executed through a share issue. The investment will be used to support the next growth chapter for Koenigsegg and further strengthens the company's position as a global leader in the megacar industry.

Majority owner Christian von Koenigsegg, through his family holding company, is also increasing his stake in the company alongside Chieftain.

Vinge’s team consisted of Magnus Pauli, Petronella Hallberg, Jenny Sandlund, Amelia Rihs, Adam Loewenstein, Michael Montner, Fredrik Löwenclou, Hanna Jansson and Anna Högsten.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025